Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.84 |
| ▸ | GAA | P10253 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | USP2 | O75604 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070839 | 0.98 | ALDH1A1 (0.84) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL4759272 | 0.88 | KMT2A (0.78) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL3450415 | 0.86 | KMT2A (0.72) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL29060821 | 0.86 | KMT2A (0.72) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL4075002 | 0.86 | L3MBTL1 (1.00) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL12386393 | 0.86 | KMT2A (0.72) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL18711452 | 0.86 | KMT2A (0.76) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL8222210 | 0.85 | KMT2A (0.70) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL18181909 | 0.85 | NPC1 (0.70) | ALDH1A1GAAKMT2AMEN1USP2 | |
| SCHEMBL10125733 | 0.84 | MAPT (0.70) | ALDH1A1GAAKMT2AMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | ALDH1A1 207/4885GAA 3857/4885KMT2A 1872/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | ALDH1A1 554/4885GAA 4207/4885KMT2A 3314/4885 |
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | ALDH1A1 1337/4885GAA 2468/4885KMT2A 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.